BioSpace News Archive

Bristol Myers Squibb is reportedly courting Canada’s Aurinia Pharmaceuticals to strike a buyout deal.

This is after the company shared positive results from its Phase III trial on Imfinzi, increasing the chances for survival in BTC patients when combined with standard-of-care chemotherapy regimens.

Some fear potential side effects, and more just aren’t sure about the quality and risks associated with a vaccine developed in an unprecedented nine months.

Sio Gene Therapies had a few big announcements last week, including a Fast Track Designation from the U.S. Food and Drug Administration and the reorganization of its R&D group.

Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.

Vicore Pharma Holding AB, a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet.

Sumitomo Heavy Industries, Ltd. has conducted proton beam acceleration tests on its in-house developed superconducting cyclotron for the next-generation proton therapy system under development and confirmed the generation of a high-intensity proton beam of 1,000 nA.

The Nomination Committee, which is to be appointed for the period until a new Nomination Committee is appointed, shall consist of four members, of which three will be appointed by the Company’s three largest shareholders in terms of voting, and the fourth shall be the Chairman of the Board.

Redwood Pharma announces a strategic move to accelerate development of RP501, the company’s IntelliGel-based topical first-line therapy for dry eye disease.

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the treatment of the first patient in its pivotal Phase 3 trial in Brazil for critically ill COVID-19 patients.